BLUE - bluebird bio, Inc.

4.82
0.050   1.037%

Share volume: 254,366
Last Updated: 04-08-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.07%

PREVIOUS CLOSE
CHG
CHG%
$4.77
0.05
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
24%
Profitability 0%
Dept financing 21%
Liquidity 58%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.63%
1 Month
22.34%
3 Months
-43.03%
6 Months
874.72%
1 Year
282.54%
2 Year
63.95%
Key data
Stock price
$4.82
P/E Ratio 
0.00
DAY RANGE
$4.77 - $5.17
EPS 
-$4.05
52 WEEK RANGE
$0.29 - $10.28
52 WEEK CHANGE
$305.04
MARKET CAP 
81.083 M
YIELD 
N/A
SHARES OUTSTANDING 
109.336 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
0.83
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$871,155
AVERAGE 30 VOLUME 
$511,838
Company detail
CEO: Andrew Obenshain
Region: US
Website: bluebirdbio.com
Employees: 520
IPO year: 2013
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

bluebird bio, Inc., researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc.

Recent news
loading